New Pill Blocks COVID After Exposure in 2,000-Person Trial

Six years into the pandemic, scientists finally have a pill that stops COVID before it starts.

The drug ensitrelvir cut symptomatic COVID cases by two-thirds in a major trial of more than 2,000 people exposed to the virus at home. While 9% of people taking a placebo developed symptoms, only 2.9% of those taking ensitrelvir got sick.

The trial focused on household contacts, one of the most common places people catch COVID. Participants started a five-day course within 72 hours of exposure to an infected family member or roommate.

Ensitrelvir works by blocking a key enzyme the virus needs to copy itself. Pfizer's Paxlovid targets the same enzyme, but Paxlovid only treats active infections. This marks the first time an antiviral has proven effective at prevention after exposure.

The results matter most for people who face serious risks from COVID. Older adults, immunocompromised patients, and residents of nursing homes now have a potential tool to avoid infection entirely when someone nearby gets sick.

Testing caught another win: only 14% of people taking ensitrelvir tested positive for the virus at all, compared to 21.5% in the placebo group. The drug reduced both symptomatic cases and silent infections.

Side effects were nearly identical between the drug and placebo groups. About 15% of participants in both groups reported mild issues like temporary cholesterol changes. No serious safety concerns emerged.

The trial ran between June 2023 and September 2024, covering multiple COVID variants. Neither participants nor researchers knew who received the real drug, making the results especially reliable.

Why This Inspires

Professor Frederick Hayden at the University of Virginia called this "the first clear demonstration" of an easily administered oral drug that protects exposed people in real-world settings. The breakthrough came from methodical science and thousands of volunteers willing to help find answers.

Japan approved ensitrelvir, sold as Xocova, for both treatment and prevention in 2024. Singapore followed with its own approval. The U.S. Food and Drug Administration will decide in June whether to make it available to Americans.

While COVID no longer dominates headlines, the virus still threatens millions of vulnerable people worldwide. Protection after exposure fills a critical gap in our defenses, especially for caregivers, family members, and healthcare workers who can't avoid contact with infected people.

The same drug that helps one household could protect entire nursing homes during outbreaks, though researchers didn't specifically test those settings yet.